Cetuximab in the management of colorectal cancer.
Cetuximab, a chimeric IgG1 monoclonal antibody that targets the ligand-binding domain of the epidermal growth factor receptor (EGFR), is active in metastatic colorectal cancer (mCRC). As an IgG1 antibody, cetuximab may exert its antitumor efficacy through both EGFR antagonism and antibody-dependent cell-mediated cytotoxicity. Clinical trials established the role of cetuximab, particularly with irinotecan, in irinotecan-refractory/heavily pretreated patients. More recent studies show promising activity in second-line treatment after oxaliplatin-based therapy failure, and with first-line chemotherapy, where increased response rates seen with adding cetuximab to first-line therapy for mCRC may increase chances for curative surgery in a population for whom the therapy goal would otherwise be palliative. Cetuximab is generally well tolerated; common toxicities are acne-form rash and hypomagnesemia. Rash intensity is associated with clinical efficacy, and in the future, may be used as a marker for optimal drug exposure. Cetuximab activity in mCRC is not correlated with EGFR expression, and consequently other markers will be needed to identify the most likely responders. Cetuximab has clinically emerged as a core agent, along with 5-fluorouracil, irinotecan, oxaliplatin, and bevacizumab, for overall mCRC management to optimize survival. Ongoing studies are exploring best combinations of cetuximab with these other agents to maximize patient outcome.
Lenz
Heinz-Josef
HJ
Division of Medical Oncology, University of Southern California/ Norris, Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, USA.
J Clin Oncol. 2000 Aug;18(16):2938-47
10944126
Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15
11597399
Lancet. 1998 Oct 31;352(9138):1413-8
9807987
J Am Acad Dermatol. 2007 Feb;56(2):317-26
17141360
Ann Oncol. 2008 Jun;19(6):1141-5
18281264
Tissue Antigens. 2003 Mar;61(3):189-202
12694568
Oncology. 2002;63(1):92-8
12187077
N Engl J Med. 2004 Jul 22;351(4):337-45
15269313
J Clin Oncol. 2006 Jul 20;24(21):3354-60
16849749
Ann Pharmacother. 1994 Feb;28(2):220-6
8173141
J Clin Oncol. 2007 Aug 20;25(24):3712-8
17704420
Cancer Res. 1999 Apr 15;59(8):1935-40
10213503
Clin Colorectal Cancer. 2006 Jul;6(2):152-6
16945172
Int J Cancer. 2007 Feb 15;120(4):781-7
17096332
Ann Oncol. 2007 Feb;18(2):305-10
17079693
Lancet. 2000 Mar 25;355(9209):1041-7
10744089
N Engl J Med. 2004 Jun 3;350(23):2335-42
15175435
J Clin Oncol. 2004 Apr 1;22(7):1209-14
15051767
J Clin Oncol. 2007 Apr 20;25(12):1539-44
17442997
J Clin Oncol. 2004 Apr 1;22(7):1201-8
14993230
Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1384-90
16979839
Clin Cancer Res. 2002 May;8(5):994-1003
12006511
Ann Oncol. 2005 Jan;16(1):102-8
15598946
J Clin Oncol. 2003 Nov 1;21(21):3940-7
12975461
Ann Oncol. 2006 Mar;17(3):450-6
16303861
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
11252954
J Clin Oncol. 2005 Dec 20;23(36):9441-2
16361649
Cancer. 2000 Jul 1;89(1):74-82
10897003
J Clin Oncol. 2004 Jan 15;22(2):229-37
14657227
Clin Cancer Res. 2007 Mar 1;13(5):1552-61
17332301
Drugs Today (Barc). 2005 Feb;41(2):107-27
15821783
Ann Oncol. 2007 Apr;18(4):738-44
17208931
Blood. 2004 Nov 1;104(9):2635-42
15226177
Cancer Res. 2006 Apr 15;66(8):3992-5
16618717
Lancet. 1998 Oct 31;352(9138):1407-12
9807986
J Clin Oncol. 2007 Oct 10;25(29):4557-61
17876013
Panminerva Med. 2001 Sep;43(3):177-209
11579331
J Clin Oncol. 2006 Oct 20;24(30):4914-21
17050875
Expert Opin Biol Ther. 2006 Nov;6(11):1229-35
17049019
J Clin Oncol. 2005 May 20;23(15):3536-44
15908664
J Clin Oncol. 2007 Aug 1;25(22):3230-7
17664471
Br J Cancer. 2007 Apr 23;96(8):1166-9
17375050
J Clin Oncol. 2005 Aug 1;23(22):5235-46
16051966
Clin Colorectal Cancer. 2005 Apr;5 Suppl 1:S19-27
15871762
J Biol Chem. 2005 Sep 2;280(35):31182-9
16000298
Clin Cancer Res. 1999 Apr;5(4):909-16
10213228
N Engl J Med. 2000 Sep 28;343(13):905-14
11006366
J Clin Oncol. 2008 Nov 20;26(33):5326-34
18854571
Cancer Metastasis Rev. 2005 Dec;24(4):487-99
16408158
J Clin Oncol. 2005 Mar 20;23(9):1803-10
15677699
J Natl Cancer Inst. 2005 Aug 17;97(16):1221-4
16106027
Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):5-13
16736978
Int J Biochem Cell Biol. 1999 Jun;31(6):637-43
10404636
J Natl Compr Canc Netw. 2003 Jan;1(1):40-53
19764149
N Engl J Med. 2006 Feb 9;354(6):567-78
16467544